This report values the global multiplex assays market at US$6.8B in 2025 and forecasts growth to US$12.4B by 2030, a 12.8% CAGR (2026-2030). North America is the largest regional market at approximately 34.0% share of 2025 demand, while Asia Pacific is the fastest-growing region at approximately 15.5% CAGR, led by China's expanding diagnostics and life-sciences manufacturing base and India's rapid research-infrastructure build-out at approximately 16.9% CAGR - the fastest of any major market covered in this report.
The global multiplex assays market grew from an estimated US$4.1B in 2021 to US$6.8B in 2025, a historical CAGR of approximately 13.5%, as laboratories shifted from singleplex to simultaneous multi-analyte testing to reduce sample volume, cost and turnaround time. By product, consumables (assay kits, reagents, beads and microplates) lead at 68% share, while software and data-analysis services are the fastest-growing category at approximately 16.0% CAGR. By assay type, protein multiplex assays are the largest category at 42% share, while nucleic-acid multiplex assays are the fastest-growing at approximately 14.5% CAGR, driven by molecular-diagnostic panel adoption and next-generation sequencing integration.
Growth is underpinned by the rising global burden of chronic and infectious disease, the expansion of precision medicine and companion diagnostics, increasing biopharmaceutical R&D investment in biomarker-driven drug development, and continued laboratory automation. Key trends reshaping the industry include the scale-up of high-plex and spatial-biology platforms, integration of artificial-intelligence-enabled data interpretation, and the expansion of syndromic and multi-biomarker clinical panels. The market's principal challenges include high instrument and validation costs, assay-development complexity, cross-reactivity and standardization hurdles, and the requirement for specialized personnel and regulatory clearance in clinical settings.
The competitive landscape is led by Thermo Fisher Scientific, Bio-Rad Laboratories, Bio-Techne, QIAGEN, Revvity, Agilent Technologies, Becton, Dickinson and Company, Quanterix and Danaher Corporation, with competitive intensity centered on multiplexing capacity, detection sensitivity, panel breadth and platform automation rather than scale alone. Looking ahead, the global multiplex assays market enters 2026 as a structurally growing industry: precision medicine, expanding companion-diagnostic requirements and continued research investment are together expected to sustain demand for higher-plex, higher-value assay platforms through 2030.
The global multiplex assays market grew from an estimated US$4.1B in 2021 to US$6.8B in 2025, a historical CAGR of approximately 13.5%, as laboratories shifted from singleplex to simultaneous multi-analyte testing to reduce sample volume, cost and turnaround time. By product, consumables (assay kits, reagents, beads and microplates) lead at 68% share, while software and data-analysis services are the fastest-growing category at approximately 16.0% CAGR. By assay type, protein multiplex assays are the largest category at 42% share, while nucleic-acid multiplex assays are the fastest-growing at approximately 14.5% CAGR, driven by molecular-diagnostic panel adoption and next-generation sequencing integration.
Growth is underpinned by the rising global burden of chronic and infectious disease, the expansion of precision medicine and companion diagnostics, increasing biopharmaceutical R&D investment in biomarker-driven drug development, and continued laboratory automation. Key trends reshaping the industry include the scale-up of high-plex and spatial-biology platforms, integration of artificial-intelligence-enabled data interpretation, and the expansion of syndromic and multi-biomarker clinical panels. The market's principal challenges include high instrument and validation costs, assay-development complexity, cross-reactivity and standardization hurdles, and the requirement for specialized personnel and regulatory clearance in clinical settings.
The competitive landscape is led by Thermo Fisher Scientific, Bio-Rad Laboratories, Bio-Techne, QIAGEN, Revvity, Agilent Technologies, Becton, Dickinson and Company, Quanterix and Danaher Corporation, with competitive intensity centered on multiplexing capacity, detection sensitivity, panel breadth and platform automation rather than scale alone. Looking ahead, the global multiplex assays market enters 2026 as a structurally growing industry: precision medicine, expanding companion-diagnostic requirements and continued research investment are together expected to sustain demand for higher-plex, higher-value assay platforms through 2030.
Table of Contents
1. Introduction
2. Global Market Analysis
3. Market Segmentation
4. Regional Market Analysis
5. Technology Landscape
6. Competitive Landscape
7. Company Profiles
8. Market Outlook
List of Tables and Figures
Companies Mentioned
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- Bio-Techne
- QIAGEN
- Revvity
- Agilent Technologies
- Becton, Dickinson and Company
- Quanterix
- Danaher Corporation
